TScan Therapeutics (TCRX) Projected to Post Earnings on Monday

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect TScan Therapeutics to post earnings of ($0.28) per share and revenue of $1.62 million for the quarter.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The business had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.62 million. On average, analysts expect TScan Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TScan Therapeutics Price Performance

TCRX stock traded down $0.10 on Friday, reaching $1.29. 244,572 shares of the company's stock were exchanged, compared to its average volume of 361,475. The stock has a fifty day moving average of $1.49 and a 200-day moving average of $2.72. The firm has a market cap of $72.72 million, a PE ratio of -1.21 and a beta of 1.06. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. TScan Therapeutics has a twelve month low of $1.02 and a twelve month high of $9.69.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Needham & Company LLC reissued a "buy" rating and set a $9.00 price target on shares of TScan Therapeutics in a research note on Tuesday, April 8th. Wedbush reaffirmed an "outperform" rating and set a $7.00 price target on shares of TScan Therapeutics in a research note on Tuesday. Morgan Stanley reaffirmed an "overweight" rating and issued a $10.00 price target on shares of TScan Therapeutics in a report on Friday, March 14th. Barclays lowered their target price on TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating on the stock in a report on Friday, March 7th. Finally, HC Wainwright dropped their price objective on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $8.50.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.